Literature DB >> 33731798

Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.

Philip A Waghorn1, Diego S Ferreira1,2, Derek J Erstad3, Nicholas J Rotile1, Ricard Masia3, Chloe M Jones1, Chuantao Tu1, Mozhdeh Sojoodi3, Yin-Ching I Chen1, Franklin Schlerman4, Jeremy Wellen4, Robert V P Martinez4, Kenneth K Tanabe3, Bryan C Fuchs3, Peter Caravan5.   

Abstract

Non-alcoholic steatohepatitis (NASH) is an increasing cause of chronic liver disease characterized by steatosis, inflammation, and fibrosis which can lead to cirrhosis, hepatocellular carcinoma, and mortality. Quantitative, noninvasive methods for characterizing the pathophysiology of NASH at both the preclinical and clinical level are sorely needed. We report here a multiparametric magnetic resonance imaging (MRI) protocol with the fibrogenesis probe Gd-Hyd to characterize fibrotic disease activity and steatosis in a common mouse model of NASH. Mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) to induce NASH with advanced fibrosis. Mice fed normal chow and CDAHFD underwent MRI after 2, 6, 10 and 14 weeks to measure liver T1, T2*, fat fraction, and dynamic T1-weighted Gd-Hyd enhanced imaging of the liver. Steatosis, inflammation, and fibrosis were then quantified by histology. NASH and fibrosis developed quickly in CDAHFD fed mice with strong correlation between morphometric steatosis quantification and liver fat estimated by MRI (r = 0.90). Sirius red histology and collagen quantification confirmed increasing fibrosis over time (r = 0.82). Though baseline T1 and T2* measurements did not correlate with fibrosis, Gd-Hyd signal enhancement provided a measure of the extent of active fibrotic disease progression and correlated strongly with lysyl oxidase expression. Gd-Hyd MRI accurately detects fibrogenesis in a mouse model of NASH with advanced fibrosis and can be combined with other MR measures, like fat imaging, to more accurately assess disease burden.

Entities:  

Year:  2021        PMID: 33731798      PMCID: PMC7971064          DOI: 10.1038/s41598-021-85679-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  63 in total

1.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

2.  Molecular MRI of collagen to diagnose and stage liver fibrosis.

Authors:  Bryan C Fuchs; Huifang Wang; Yan Yang; Lan Wei; Miloslav Polasek; Daniel T Schühle; Gregory Y Lauwers; Ashfaq Parkar; Anthony J Sinskey; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2013-07-06       Impact factor: 25.083

3.  Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression.

Authors:  Lorenzo A Orci; Karim Gariani; Graziano Oldani; Vaihere Delaune; Philippe Morel; Christian Toso
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-04       Impact factor: 11.382

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Authors:  Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2016-10-27       Impact factor: 22.682

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

7.  Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.

Authors:  James M Paik; Pegah Golabi; Youssef Younossi; Alita Mishra; Zobair M Younossi
Journal:  Hepatology       Date:  2020-10-27       Impact factor: 17.425

8.  Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.

Authors:  Derek J Erstad; Mozhdeh Sojoodi; Martin S Taylor; Veronica Clavijo Jordan; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs; Christian T Farrar; Andrea L Axtell; Nicholas J Rotile; Chloe Jones; Katherine A Graham-O'Regan; Diego S Ferreira; Theodoros Michelakos; Filippos Kontos; Akhil Chawla; Shen Li; Sarani Ghoshal; Yin-Ching Iris Chen; Gunisha Arora; Valerie Humblet; Vikram Deshpande; Motaz Qadan; Nabeel Bardeesy; Cristina R Ferrone; Michael Lanuti
Journal:  Clin Cancer Res       Date:  2020-07-01       Impact factor: 12.531

9.  Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Authors:  Derek J Erstad; Christian T Farrar; Sarani Ghoshal; Ricard Masia; Diego S Ferreira; Yin-Ching Iris Chen; Ji-Kyung Choi; Lan Wei; Phillip A Waghorn; Nicholas J Rotile; Chuantao Tu; Katherine A Graham-O'Regan; Mozhdeh Sojoodi; Shen Li; Yang Li; Guogiang Wang; Kathleen E Corey; Yat Sun Or; Lijuan Jiang; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs
Journal:  Hepatol Commun       Date:  2018-05-21

10.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.

Authors:  Masahiko Matsumoto; Natsuko Hada; Yoshiyuki Sakamaki; Akiko Uno; Toshihiko Shiga; Chiaki Tanaka; Tsuneo Ito; Asao Katsume; Masayuki Sudoh
Journal:  Int J Exp Pathol       Date:  2013-01-11       Impact factor: 1.925

View more
  1 in total

1.  Lysyl oxidase regulation and protein aldehydes in the injured newborn lung.

Authors:  Ying Zhong; Rose C Mahoney; Zehedina Khatun; Howard H Chen; Christopher T Nguyen; Peter Caravan; Jesse D Roberts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-08       Impact factor: 5.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.